Biodesix(US:BDSX)2025-11-03 21:02Revenue Performance - Q3 2025 revenue reached $21.8 million, a 20% increase compared to Q3 2024[1] - Total revenues for Q3 2025 reached $21.768 million, a 20.5% increase from $18.151 million in Q3 2024[21] - Lung Diagnostic Testing revenue was $19.8 million for Q3 2025, up 16% from the prior year, driven by increased tests delivered and average revenue per test[3] - Development Services revenue surged to $1.9 million for Q3 2025, marking a 97% increase year-over-year[3] - Total revenues for the nine months ended September 30, 2025, were $59.744 million, a 17.3% increase from $50.894 million in the same period of 2024[21] Profitability Metrics - Gross profit margin for Q3 2025 was 81%, reflecting a 400-basis point improvement year-over-year[1] - Net loss for Q3 2025 was $8.7 million, an improvement of 15% over the prior year[10] - Adjusted EBITDA loss for Q3 2025 was $4.6 million, improving by 18% compared to the previous year[10] - Net loss for Q3 2025 was $8.716 million, an improvement from a net loss of $10.258 million in Q3 2024[23] - Adjusted EBITDA for Q3 2025 was $(4.591) million, compared to $(5.584) million in Q3 2024, indicating a narrowing loss[23] - The company reported a net loss per share of $1.16 for Q3 2025, an improvement from $1.40 in Q3 2024[21] Expenses Overview - Research and development expenses increased to $2.992 million in Q3 2025, up from $2.547 million in Q3 2024[21] - Total operating expenses for Q3 2025 were $28.819 million, compared to $26.742 million in Q3 2024, reflecting a 7.7% increase[21] - Sales, marketing, general and administrative expenses rose to $21.714 million in Q3 2025, compared to $20.016 million in Q3 2024[21] Cash Position - Cash and cash equivalents as of September 30, 2025, were $16.6 million, down $4.1 million from June 30, 2025[10] Strategic Developments - The company expanded its partnership with Bio-Rad Laboratories to develop high complexity assays[10] - Lung Diagnostic Tests ordered in primary care increased by over 75% compared to Q3 2024[10] Shareholder Information - Weighted-average shares outstanding increased to 7.500 million in Q3 2025 from 7.315 million in Q3 2024[21]